Wilk: The Bridge Route, From Cosmetics and Yogurt to the Question of What Counts as Real Commercialization

The Bridge Is No Longer Just the Route, It Is the Product

The main article already established that the loss narrowed, but broad commercial proof was still missing. This follow-up isolates what Wilk actually chose to do in 2025: not to jump straight into a near-term full cultured milk story, but to build a narrower bridge route through biomimicry, cosmetics, and yogurt.

That distinction matters because it is easy to read the Bio-Leaf, Mami-Care, Chillion, and Prio thread as if the company has already entered commercialization. That is too strong a read. What the filing actually describes is a move from isolated research into market-facing attempts through products that use Wilk’s know-how, but do not yet require the full proof burden of commercial-scale cultured milk.

In other words, two things need to be separated. The first is bridge commercialization: cosmetics and food products that try to bring Wilk’s know-how to market through mimicked ingredients, encapsulation, and third-party manufacturing partners. The second is core commercialization: commercial production of cultured milk components, especially cultured fat, with scale-up, cost economics, milestones, and a formal commercialization plan that are still not fully in place.

The filing itself draws that line clearly. On one side, the company says it has adopted a near-term biomimicry strategy that allows it to express its accumulated know-how without complex regulation and without buying unique scale-up equipment. On the other side, the same report says the Yissum research period has been extended through February 28, 2027, that there are still no commercialization milestones, and that the company has not yet reached commercial product production.

That is the heart of the thesis. Wilk did move closer to market, but through a bridge route designed to prove applicability, not through full proof that the cultured-milk economics are already working.

What Wilk Actually Chose to Commercialize Now

The 2025 strategic choice is clearer than it looks at first glance. The company did not abandon the cultured-milk vision, but it did defer the attempt to commercialize it directly in the near term. Instead, it chose to bring products to market that are based on its knowledge and analytical capabilities through mimicked ingredients, encapsulation, and outside manufacturing partners.

The advantage of that route is stated explicitly in the filing: it currently bypasses complex regulation and the need to buy expensive scale-up equipment. That is not just a technical convenience. It is also an implied admission that Wilk’s current bottleneck is not only scientific. It is also regulatory and industrial. If the company can get a cosmetics product or a yogurt product to market before proving broad commercial production of cultured milk components, it buys itself time, learning, and perhaps a first market proof point.

That also explains why the MOU with The Fat Company did not progress into a full agreement. The company says outright that the reason was its desire to focus on cosmetics and yogurt. So this was not only about lacking resources. It was also a route choice: first products with potentially shorter development, regulatory, and customer-conversion cycles, and only later a broader expansion.

The Cosmetics Chain: Real Progress, but Through Several Gates That Are Still Closed

The cosmetics route is not cosmetic in the empty sense of the word. There is a real industrial chain here: Bio-Leaf is supposed to provide the encapsulation layer, Mami-Care was selected for the breastfeeding ointment, Chillion is developing the cream and serum and is also manufacturing Wilk’s products, and by the report date five products had already been submitted for regulatory approval with the Ministry of Health.

At the same time, every critical stage is still written in conditional language.

With Mami-Care, the start of mass production is conditioned on completion of development, on regulatory approvals, and on distributor orders. So even if development works, the product still has to clear regulation and prove that someone is willing to take it to shelf.

With Chillion, the picture is somewhat further advanced but not much cleaner. The company reported 3 prototypes, real development of 2 shelf products, completion of the serum formulation, and 5 products already submitted for approval. That is no longer a conceptual slide deck. It is a product pipeline. But here too, the move into mass production depends on regulatory approval and on distributor orders.

There is another layer that is easy to miss: in both Mami-Care and Chillion, the Bio-Leaf arrangements still have not matured into a full agreement. That means the technology layer that underpins the joint product still rests on MOUs and development progress, not on a finalized broader commercial contract. So even if Wilk moves closer to serial production of cosmetics products, it is still dependent on a partner chain whose key enabling link is not yet fully closed.

The analytical implication is two-sided. On the one hand, cosmetics is Wilk’s most advanced route into a real market. On the other hand, what it may prove in 2026 is formulation, regulatory, and partner-manufacturing capability, not proof that the cultured core is already ready for economic production at industrial scale.

The Yogurt Route: An Important Step, but Still Not a Sale

Prio is probably the most interesting case because it looks closest to revenue. The company describes a plant-based MFGL product that mimics the structure and composition of human milk fat, protected in a microcapsule developed with Bio-Leaf, and successfully integrated into the manufacturer’s yogurt products.

That matters because it moves Wilk from a laboratory prototype to a simpler industrial question: can the development be integrated into an existing product without damaging taste or product characteristics. According to the filing, the initial answer is yes.

But even here, the word commercialization is still premature. In December 2025, the company signed a conditional advance agreement under which the manufacturer would transfer an amount equal to 20% of the total transaction value. In note form, that is roughly NIS 20 thousand out of a NIS 100 thousand transaction plus VAT, and in the immediate-report framing it is about NIS 23 thousand out of roughly NIS 118 thousand including VAT. Economically, it is the same event from accounting and gross-value angles.

The important point is not the size of the advance. The important point is the conditions around it. If the company does not receive the relevant regulatory approvals within 6 months, or if the final joint development does not meet the manufacturer’s requirements, the advance must be returned. More than that, the accounting note states explicitly that completion of the deal and revenue recognition are subject to those conditions.

That is a material distinction. Prio is no longer only a test, but it is also still not a sale. It is a conversion test: can Wilk take a development that worked in an initial integration process with a manufacturer, clear regulation, satisfy that manufacturer, and then turn it into an actual purchase.

This is why the conditional one-ton raw-material order that Wilk references in 2026 is a positive commercial signal, but not final proof. As long as the agreement still depends on regulatory approval and final manufacturer acceptance, the market is looking at a conditional commercial option, not a completed sale.

The Three Clocks That Need to Be Read Correctly

The best way to understand Wilk’s commercialization story right now is not through one product, but through three clocks running in parallel.

That is the data point that organizes the difference between progress and real commercialization. On the short clock, Wilk is already moving through manufacturers, formulations, and approvals. On the long clock, the company is still sitting before a formal commercialization plan has even been defined with Yissum.

That gap matters especially because the company itself writes that the first product it is expected to focus on for commercial production will be cultured fat. So the core has not disappeared. It is still framed as the likely first commercial focus. But in that same section the company also says that after the joint experiment with Pluri/Pluristem, it concluded there is scale-up feasibility, while production cost still needs to come down, and that the current strategy is to perform scale-up through third parties rather than through self-funded investment in expensive equipment.

That is a much more sober picture. There is a technology direction. There is a partner pointing to a scale-up path. There is even a declared commercial focus on cultured fat. But there is still no commercial line, no signed commercialization milestones with Yissum, and no proof that cultured-fat production cost has already moved to a level that supports a real commercial business.

What Would Count Here as Real Commercialization

For the word commercialization to carry a different weight, Wilk has to pass four clear tests.

First, the cosmetics route has to move from regulatory approval into actual distributor orders and real mass production. Approval alone is important, but it still does not mean the product sold or came back for repeat production.

Second, Prio has to move from a conditional advance into recognized revenue and an actual purchase. That is the cleanest test of all: does the money stay, and does the transaction close.

Third, the Bio-Leaf layer has to move from MOUs and development progress into a full commercial framework that supports the cosmetics and food chain.

Fourth, and probably most important, the cultured-fat path has to move from a future focus statement into a commercialization plan with milestones, a clearer role split with Yissum, and production cost that is actually moving toward viability. Without that, Wilk can prove there is a market for bridge products, but not necessarily that it has proved the engine on which the original story was built.

Bottom Line

Wilk did not move away from commercialization. It changed the definition of it. Instead of trying to prove full cultured milk right now, it built a bridge route that starts with products closer to market, with outside manufacturing partners, lighter regulation, and a shorter loop for measuring customer response.

That is a rational move. It may also create real value, because if the cosmetics products receive approval and move into production, and if Prio turns from a conditional order into a completed transaction, Wilk will be able to show for the first time not only science, but translation into market activity.

But precision matters. The bridge route can prove that Wilk knows how to formulate a product, clear regulation, and work with manufacturing partners. It still does not prove that the company has solved commercialization of the cultured core. Yissum has been extended through 2027 without fixed commercialization milestones, cultured-fat scale-up still depends on third parties, and production cost remains central.

So the right 2026 question is not only whether Wilk can launch a first product. The right question is what kind of proof that product would provide. Right now, the report is clear: first comes bridge proof. Core proof, if it comes, still belongs to the next stage.